As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

HEALTH chiefs are being urged to cut red tape that is denying NHS cancer patients drugs that could prolong their lives. The National Institute for Health and Care Excellence is accused of setting ...

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.

AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...